ALEFACEPT: A novel biologic in the treatment of psoriasis

Drugs of Today

Volumn 40, Issue 12, 2004, Pages 961-974

  Liu, Clive M ^a   McKenna, Jeffrey K ^a   Krueger, Gerald G ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEFACEPT; ANTIGEN; DRUG ANTIBODY; HYBRID PROTEIN;

ADULT DISEASE; APOPTOSIS; ARTHRALGIA; CANCER RISK; CELLULAR IMMUNITY; CLINICAL TRIAL; CYTOKINE RELEASE; DISEASE SEVERITY; DIZZINESS; DOSE CALCULATION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFECT; DRUG ELIMINATION; DRUG RESPONSE; DRUG SPECIFICITY; DRUG TOLERABILITY; FLU LIKE SYNDROME; HEADACHE; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL MEMORY; IMMUNOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; LYMPHOCYTE DEPLETION; LYMPHOCYTE TRANSFER; MEMORY CELL; MULTIPLE DRUG DOSE; NAUSEA; OFF TREATMENT RESPONSE; OPPORTUNISTIC INFECTION; PHARYNGITIS; PHOTOCHEMOTHERAPY; PHOTOTHERAPY; PRURITUS; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; REVIEW; SYSTEMIC THERAPY; T LYMPHOCYTE ACTIVATION;

DERMATOLOGIC AGENTS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; INJECTIONS, INTRAVENOUS; MALE; PSORIASIS; RADIOTHERAPY, ADJUVANT; RECOMBINANT FUSION PROTEINS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 12344263966     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2004.40.12.872572     Document Type: Review

References (52)

1. Gottlieb, A., Krueger, J.G., Bright, R. et al. Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis. J Am Acad Dermatol 2000, 42: 428-35.
2. Christophers, E. Psoriasis-epidemiology and clinical spectrum. Clin Exp Dermatol 2001, 26: 314-20.
3. National Psoriasis Foundation. Facts, About Psoriasis: http://www.psoriasis.org. Accessed 11/21/03.
4. Fortune, D.G., Main, C.J., O'Sullivan, T.M., Griffiths, C.E.M. Quality of life in patients with psoriasis: the contribution of clinical variables and psoriasis-specific stress. Br J Dermatol 1997, 137: 755-60.
5. Krueger, G.G., Koo, J., Lebwohl, M. et al. The impact of psoriasis on quality of life: Results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001, 137: 280-4.
6. Lebwohl, M., Ali, S. Treatment of psoriasis. Part 1. Topical therapy and phototherapy. J Am Acad Dermatol 2001, 45: 487-98; quiz 499-502.
7. Lebwohl, M., Ali, S. Treatment of psoriasis. Part 2. Systemic therapies. J Am Acad Dermatol 2001, 45: 649-61; quiz 662-4.
8. Vallat, V.P., Gilleaudeau, P., Battat, L. et al. PUVA bath therapy strongly suppresses immunological and epidermal activation in psoriasis: A possible cellular basis for remittive therapy. J Exp Med 1994, 180: 283-96.
9. Stern, R.S., Liebman, E.J., Vakeva, L. Oral psoralen and ultraviolet-A light (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer. PUVA Follow-up Study. J Natl Cancer Inst 1998, 90: 1278-84.
10. Stern, R.S. The risk of melanoma in association with long-term exposure to PUVA. J Am Acad Dermatol 2001, 44: 755-61.
11. Zachariae, H. Long-term use of cyclosporine in dermatology. Arch Dermatol 1996, 132: 692-4.
12. Tung, J.P., Maibach, H.I. The practical use of methotrexate in psoriasis. Drugs 1990, 40: 697-712.
13. Ashcroft, D.M., Li Wan Po, A., Griffiths, C.E. Therapeutic strategies for psoriasis. J Clin Pharm Ther 2000, 25: 1-10.
14. Katz, H.I., Waalen, J., Leach, E.E. Acitretin in psoriasis: An overview of adverse effects. J Am Acad Dermatol 1999, 41 (3 Pt. 2): S7-S12.
15. Koo, J., Lebwohl, M. Duration of remission of psoriasis therapies. J Am Acad Dermatol 1999, 41: 51-9.
16. Linden, K.G., Weinstein, G.D. Psoriasis: Current perspectives with an emphasis on treatment. Am J Med 1999, 107: 595-605.
17. Barker, J.N. Psoriasis as a T cell-mediated autoimmune disease. Hosp Med 1998, 59: 530-3.
18. Robert, C., Kupper, T.S. Inflammatory skin diseases, T cells, and immune surveillance. N Engl J Med 1999, 341: 1817-28.
19. Gordon, K.B., West, D.P. Biologic therapy in dermatology. In: Comprehensive Dermatologic Drug Therapy, W.S. (Ed.). 2001: W.B. Saunders, Co. 928-42.
20. Majeau, G.R., Meier, W., Jimmo, B., Kioussis, D., Hochman, P.S. Mechanism of lymphocyte function-associated molecule 3-Ig fusion proteins inhibition of T cell responses. Structure/function analysis in vitro and in human CD2 transgenic mice. J Immunol 1994, 152: 2753-67.
21. Sanders, M.E., Makgoba, M.W., Sharrow, S.O. et al. Human memory T lymphocytes express increased levels of three cell adhesion molecules (LFA-3, CD2, and LFA-1) and three other molecules (UCHL 1, CDw29, and Pgp-1) and have enhanced IFN-gamma production. J Immunol 1988, 140: 1401-7.
22. Majeau, G.R., Whitty, A., Yim, K., Meier, W., Hochman, P.S. Low affinity binding of an LFA-3/IgG1 fusion protein to CD2+ T cells is independent of cell activation. Cell Adhes Commun 1999, 7: 267-79.
23. Magilavy, D., Mant, T., Norman, P. et al. Pharmacodynamic effects of LFA3TIP (Amevive) in patients with chronic plaque psoriasis (CPP): Selective modulation of CD45RO+ lymphocytes. J Invest Dermatol 1999, 112: 609 (Abstr. 518).
24. Ellis, C.N., Krueger, G.G. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001, 345: 248-55.
25. Ellis, C., Gordon, K., Shrager, D., for the Alefacept Clinical Study Group. Repeated courses of alefacept therapy in chronic plaque psoriasis provide consistent efficacy and safety. J Eur Acad Dermatol Venereol 2001, 15 (Suppl. 2): 246 (Abstr. P24-38).
26. Christophers, E., Braeutigam, M., Griffiths, C. et al. Study design and demographics of a randomized, double-blind, placebo-controlled phase 3 dose-comparison study to evaluate weekly intramuscular administration of alefacept in chronic plaque psoriasis. J Eur Acad Dermatol Venereol 2001, 15 (Suppl. 2): 249 (Abstr. P24-47).
27. Lebwohl, M., Brown, R., Ellis, C. et al. Study design and demographics of a randomized, double-blind, placebo-controlled phase 3 study to evaluate weekly iv bolus administration of alefacept in chronic plaque psoriasis. J Eur Acad Dermatol Venereol 2001, 5 (Suppl. 2): 248 (Abstr. 24-26).
28. Krueger, G.G., Papp, K.A., Stough, D.B. et al. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 2002, 47: 821-33.
29. Langley, R., C.E., Lebwohl, M. Efficacy and safety of multiple courses of intramuscular alefacept in patients with chronic plaque psoriasis. J Invest Dermatol 2002, 119: 344 (Abst. 820).
30. Lebwohl, M., Christophers, E., Langley, R. et al. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 2003, 139: 719-27, (#30).
31. Vaishnaw, A.K., Casale, T.B. Alefacept is efficacious in a broad spectrum of patients with psoriasis, including those with severe disease. In: 61st Annual Meeting of the American Academy of Dermatology, San Francisco 2003.
32. van de Kerkhof, P., Vaishnaw, A.K., Kragballe, K., Ortonne, J.P. Alefacept is efficacious in a broad spectrum of patients with psoriasis. Poster presented at the 1st International Spring Symposium of the European Academy of Dermatology and Venereology 2003, Malta.
33. Christophers, E., O'Gorman, J., Vaishnaw, A.K., Pooled efficacy of alefacept in psoriasis patients who are refractory or have contraindications to other psoriasis systemic treatments or phototherapies. In: 9th International Psoriasis Symposium, New York 2003.
34. Gordon, K.B., Vaishnaw, A.K., O'Gorman, J. et al. Treatment with alefacept is associated with prolonged remissions in patients with chronic plaque psoriasis. In: 9th International Psoriasis Symposium, New York 2003.
35. Koo, J. Combination therapy with alefacept plus broadband ultraviolet B light for treatment of psoriasis. In: International Psoriasis Symposium, New York 2003.
36. Ortonne, J.P., Khemis, A. Combination therapy for alefacept plus narrowband ultraviolet B light for treatment of psoriasis. In: International Psoriasis Symposium, New York 2003.
37. Gordon, K.B., Vaishnaw, A.K., O'Gorman, J. et al. Treatment of psoriasis with alefacept. Correlation of clinical improvement with reductions of memory T-cell counts. Arch Dermatol 2003, 139: 1563-70.
38. Margolis, D., Bilker, W., Hennessy, S. et al. The risk of malignancy associated with psoriasis. Arch Dermatol 2001, 137: 778-83.
39. Baker, B.S., Swain, A.F., Valdimarsson, H., Fry, L. T-cell subpopulations in the blood and skin of patients with psoriasis. Br J Dermatol 1984, 110: 37-44.
40. Baker, B.S., Swain, A.F., Valdimarsson, H., Fry, L. Epidermal T lymphocytes and HLA-DR expression in psoriasis. Br J Dermatol 1984, 110: 555-64.
41. Bos, J.D., Hagenaars, C., Das, P.K., Krieg, S.R., Voorn, W.J., Kapsenberg, M.L. Predominance of "memory" T cells (CD4+, CDw29+) over "naive" T cells (CD4+, CD45R+) in both normal and diseased human skin. Arch Dermatol Res 1989, 281: 24-30.
42. Friedrich, M., Krammig, S., Henze, M., Docke, W.D., Sterry, W., Asadullah, K. Flow cytometric characterization of lesional T cells in psoriasis: Intracellular cytokine and surface antigen expression indicates an activated, memory/effector type 1 immunophenotype. Arch Dermatol Res 2000, 292: 519-21.
43. Bata-Csorgo, Z., H.C., Voorhees, J.J., Cooper, K.D. Intralesional T-lymphocyte activation as a mediator of psoriatic epidermal hyperplasia, J Invest Dermatol 1995, 105 (1 Suppl.): 89S-94S.
44. Austin, L.M. et al. The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: A type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J Invest Dermatol 1999, 113: 752-9.
45. Bos, J.D., De Rie, M.A. The pathogenesis of psoriasis: Immunological facts and speculations, Immunol Today 1999, 20: 40-6.
46. Kobayashi, S., Sugiyama, H., Gyulai, R. et al. Alefacept treatment for psoriasis reduces the number of infiltrating IFN +-producing T cells in lesional skin. J Invest Dermatol 2001, 117: 546 (Abstr. 938).
47. Vaishnaw, A.K., Lee, S. Concomitant use of alefacept and immunosuppressants in patients with psoriasis. In: 61st Annual Meeting of the American Academy of Dermatology, San Francisco 2003.
48. Gottlieb, A, C.T., Goffe, B. et al. Impact of a 12-week course of alefacept therapy on primary and secondary immune responses in psoriasis patients. J Eur Acad Dermatol Venereol 2001, 15 (Suppl. 2): 242 (Abst. P24-21).
49. Tenhoor, C., Vaishnaw, A.K. Tolerability, biological activity, and pharmacokinetics of alefacept administered as an intravenous infusion, intramuscular injection, and intravenous bolus injection. J Eur Acad Dermatol Venereol 2001, 15 (Suppl. 2): 251 (Abstr. P24-56).
50. Baluna, R., Vitetta, E.S. Vascular leak syndrome: A side effect of immunotherapy. Immunopharmacology 1997, 37 (2-3): 117-32.
51. Slifka, M.K., Whitton, J.L. Clinical implications of dysregulated cytokine production. J Mol Med 2000, 78: 74-80.
52. Delves, P.J., Roitt, I.M. The immune system. First of two parts. N Engl J Med 2000, 343: 37-49.